Muromonab CD3 oral - Therapix Biosciences

Drug Profile

Muromonab CD3 oral - Therapix Biosciences

Alternative Names: aCD3; aCD3 MAb; Anti-CD3 oral immunotherapy; OKT-3 oral - NasVax; Oral anti-CD3 MAb; TRX 318

Latest Information Update: 03 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Brigham and Womens Hospital
  • Developer Therapix Biosciences
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C; Non-alcoholic steatohepatitis; Type 1 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 03 Oct 2016 Discontinued - Phase-II for Hepatitis C in Austria (PO)
  • 03 Oct 2016 Discontinued - Phase-II for Hepatitis C in Poland (PO)
  • 03 Oct 2016 Discontinued - Phase-II for Non-alcoholic steatohepatitis in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top